Blockchain can pave the way for a more value-based healthcare system, report suggests
According to a new market intelligence report by BIS Research, titled "Global Blockchain in Healthcare Market- Analysis and Forecast, 2017-2025," blockchain in healthcare is estimated to be $176.8mn in 2018, and is estimated to grow over $5.61bn by the end of 2025.
The development in providing efficient healthcare services is extensively dependent on technological advances in information technology, and particularly the ability to record and store information conveniently and economically and share it securely among different applications and systems.
Blockchain technology is being touted as the panacea for all of healthcare's information system interoperability and security-related challenges.
Blockchain can play a critical role in overcoming the shortcomings and challenges associated with legal systems. Some of the significant advantages of employing blockchain are the introduction of transparency, complete elimination of third-party intermediaries, and streamlining of operational processes and large costs.
Additionally, blockchain can pave the way for the movement to a more value-based healthcare system, improve patient engagement and even open opportunities for the introduction of more consumer-centric product segments and revenue streams.
“Around 14% of healthcare organisations are expected to have a blockchain based system in place by the end of 2018, while 70% are expected to have invested in getting the technology on-board by 2020,” explains Pushplata Patel, an analyst at BIS Research.
- Navigating regulations to launch OTC consumer health products
- Top areas of healthcare impacted by GDPR
- BenevolentAI secures $2bn valuation after raising $115mn in funding
“Various successful use-cases of blockchain have already been piloted, ranging from tracking of consent in clinical trials, development of healthcare information exchange platforms, to pharma supply chain solutions. Healthcare data exchange, health insurance, and clinical trials are expected to witness large disruption in the coming years. "
The adoption of blockchain could save the healthcare industry up to $100-$150bn per year by 2025 in data breach-related costs, IT costs, operations costs, support function costs and personnel costs, and through a reduction in frauds and counterfeit products, the report has found.
Pharmaceutical companies will be the main winners, as they lose approximately $200bn to counterfeit drugs each year. By providing complete visibility and transparency throughout the drug supply chain, blockchain will allow tracking of drugs to their point of origin and thus, help to eliminate falsified medication, reducing revenue loss by up to $43bn annually for pharma companies
The use of blockchain for healthcare data exchange will also contribute the largest market share to blockchain in the healthcare market throughout the forecast period, reaching a value of $1.89bn by 2025.
This growth is due to the use of blockchain to solve the most widespread problem in healthcare information systems related to interoperability and non-standardisation that has created data silos in the industry.
NHS opens 8 clinical trial sites to assess cancer treatment
The UK's National Health Service (NHS) is opening eight clinical trial sites to assess patients' responses to personalised cancer therapy.
The trials will analyse how patients diagnosed with advanced melanoma or non-small cell lung cancer respond to immunotherapy, to help predict their response to treatment. They will be hosted at Gloucestershire Hospitals NHS Foundation Trust facilities.
Immunotherapy helps the body's own immune system fight cancer, but while it has achieved good results for some cancer patients, it is not successful for everyone. Finding ways to predict which people will respond to the treatment is a major area of research.
OncoHost, an oncology startup, will provide advanced machine learning technology to develop personalised strategies aiming to improve the success rate of the cancer therapy. The trials will contribute to OncoHost’s ongoing PROPHETIC study, which uses the company’s host response profiling platform, PROphet®.
“Immunotherapy has achieved excellent results in certain situations for several cancers, allowing patients to achieve longer control of their cancer with maintained quality of life and longer survival,” said Dr David Farrugia, Consultant Medical Oncologist at NHS, and chief investigator of all eight NHS clinical trial sites.
“However, success with immunotherapy is not guaranteed in every patient, so this PROPHETIC study is seeking to identify changes in proteins circulating in the blood which may help doctors to choose the best treatment for each patient."
"I am excited that Gloucestershire Oncology Centre and its research department have this opportunity to contribute to this growing field of research and I am determined that our centre will make a leading national contribution in patient recruitment.”
Previous studies in the US and Israel have shown that PROphet® has high accuracy in predicting how patients with cancer will respond to various therapies.